MultipleSclerosis – www.brainwork.md

8th February 2022

Paediatric MS: What we know and what we still need to learn

https://www.brainwork.md/content/uploads/2022/02/MPR919-MS-State-Of-The-Art-Symposium-Figures-V00-07-20220207_Article3_3_Article3.png 5692 3201 Samyuktha Pillai, PhD Samyuktha Pillai, PhD https://secure.gravatar.com/avatar/981577e3a109d180cedfa959ec71e907?s=96&d=mm&r=g 8th February 2022 14th February 2022

The landscape of paediatric multiple sclerosis (MS) is rapidly evolving. In her presentation titled ‘Pediatric MS – Current treatment strategies and future directions’ at the MS State of the Art…

Samyuktha Pillai, PhD
0
0

7th February 2022

Multiple sclerosis management in the elderly

https://www.brainwork.md/content/uploads/2022/02/MPR919-MS-State-Of-The-Art-Symposium-Figures-V00-06-20220207_Article4_Article4.png 5692 3201 Samyuktha Pillai, PhD Samyuktha Pillai, PhD https://secure.gravatar.com/avatar/981577e3a109d180cedfa959ec71e907?s=96&d=mm&r=g 7th February 2022 14th February 2022

The life expectancy in multiple sclerosis (MS) continues to increase and is now comparable to that of the general population.1 This increase comes with the challenge of learning how to…

Samyuktha Pillai, PhD
0
0

3rd February 2022

Preliminary results from stem cell transplantation as an MS therapy in Switzerland

https://www.brainwork.md/content/uploads/2022/02/MPR919-MS-State-Of-The-Art-Symposium-Figures-V00-01-20220202_Article1.png 5692 3201 Samyuktha Pillai, PhD Samyuktha Pillai, PhD https://secure.gravatar.com/avatar/981577e3a109d180cedfa959ec71e907?s=96&d=mm&r=g 3rd February 2022 14th February 2022

Autologous hematopoietic stem cell transplantation (aHSCT) has been used in the treatment of multiple sclerosis (MS) since 1995 and was approved in Switzerland in June 2018. In their presentation ‘Stem…

Samyuktha Pillai, PhD
0
0

3rd February 2022

MS 2022: Upcoming therapies, and their pros and cons

https://www.brainwork.md/content/uploads/2022/02/MPR919-MS-State-Of-The-Art-Symposium-Figures-V00-01-20220202_Article2.png 5692 3201 Samyuktha Pillai, PhD Samyuktha Pillai, PhD https://secure.gravatar.com/avatar/981577e3a109d180cedfa959ec71e907?s=96&d=mm&r=g 3rd February 2022 14th February 2022

The repertoire of available multiple sclerosis (MS) disease modifying therapies (DMTs) is constantly growing. In recent years, there have been several new DMTs that have entered the market. In his…

Samyuktha Pillai, PhD
0
0

14th January 2022

What are the implications for the third COVID-19 vaccine on CD-20-depleted people with MS – Oliver Findling reports

https://www.brainwork.md/content/uploads/2022/01/Brainwork-what-are-the-implications-for-the-third-COVID-19-vaccine-on-CD-20-depleted-people-with-MS.jpg 1500 1001 Shawn Haigh Shawn Haigh https://secure.gravatar.com/avatar/d4448de12cafdc782da0f7b369642f0e?s=96&d=mm&r=g 14th January 2022 25th January 2022

In a guest post on “The MS Blog,” Dr Oliver Findling summarised a recent study on which he was the principal investigator: Humoral Immune Response after the Third SARS-CoV-2 mRNA…

Shawn Haigh
0
0

29th October 2021

Getting the complete clinical picture: A closer look at smouldering MS

https://www.brainwork.md/content/uploads/2021/10/MPR919-Brainwork-ECTRIMS-Illustrations-V00-05-20211012_illustration-02_inflammation-.png 6641 3734 Howard Donohue, PhD Howard Donohue, PhD https://secure.gravatar.com/avatar/7d0af6ce1f456871ef502d2e984812d6?s=96&d=mm&r=g 29th October 2021 24th January 2022

Multiple sclerosis (MS) is an inflammatory disease that is often dominated by relapsing-remitting symptoms.1 However, inflammation is not only present in acute and relapsing MS, but also in the secondary…

Howard Donohue, PhD
0
0

29th October 2021

Expanded interval dosing of natalizumab: Outcomes from the NOVA study

https://www.brainwork.md/content/uploads/2021/10/MPR919-Brainwork-ECTRIMS-Illustrations-V00-05-20211012_illustration-04_antibody.png 6641 3734 Howard Donohue, PhD Howard Donohue, PhD https://secure.gravatar.com/avatar/7d0af6ce1f456871ef502d2e984812d6?s=96&d=mm&r=g 29th October 2021 1st November 2021

Natalizumab 300 mg every 4 weeks (Q4W) is approved for the treatment of relapsing-remitting multiple sclerosis (MS). In patients previously exposed to the JC virus, natalizumab is associated with a…

Howard Donohue, PhD
0
0

20th October 2021

To stay or to switch? Assessing long-term treatment outcomes and impact of treatment on patients’ quality of life

https://www.brainwork.md/content/uploads/2021/10/MPR919-Brainwork-ECTRIMS-Illustrations-V00-05-20211012_illustration-03_stay_or_switch.png 6641 3734 Howard Donohue, PhD Howard Donohue, PhD https://secure.gravatar.com/avatar/7d0af6ce1f456871ef502d2e984812d6?s=96&d=mm&r=g 20th October 2021 29th October 2021

The main concerns of patients, regarding their treatment, include disease control and safety, but they also want to make sure that their day-to-day life remains as close to normal as…

Howard Donohue, PhD
0
0